Koike M, Chumakov A M, Takeuchi S, Tasaka T, Yang R, Nakamaki T, Tsuruoka N, Koeffler H P
Department of Medicine, Cedars-Sinai Medical Center, UCLA School of Medicine 90048, USA.
Leuk Res. 1997 Sep;21(9):833-9. doi: 10.1016/s0145-2126(97)00072-6.
We and others have cloned a novel human gene CCAAT/enhancer-binding protein epsilon (C/EBP-epsilon) encoding a member of the C/EBP gene family. It is exclusively expressed in myeloid and T-lymphoid cells and appears to have an important role in inducing expression of several myeloid-specific genes. We used a polymerase chain reaction (PCR)-based technique to examine DNA from 93 hamster/human radiation hybrid clones in order chromosomally to map C/EBP-epsilon to 14q11.2 (between D14S264 and D14S275) which is telomeric to the T-cell receptor alpha and delta genes and centromeric to several other myeloid gene products including Cathepsin G (CTSG) and Chymase-1 (CMA1). To determine whether C/EBP-epsilon behaves as an altered tumor-suppressor gene, samples from patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) evolving to AML were studied for loss of heterozygosity (LOH) using microsatellite sequences that we identified within 0.2 kb of the amino-terminus of the human C/EBP-epsilon gene. Allelic loss of the C/EBP-epsilon gene was detected in four out of 20 (20%) evolving MDS cases and in none of the 17 AML and 17 T-cell leukemia cases. Mutational analysis of the gene was performed using PCR-SSCP on 37 AML and 40 MDS cases including those with LOH at the gene. No abnormalities were found suggesting that the altered gene in this region is not C/EBP-epsilon. Also, C/EBP-epsilon was examined by Southern blot analysis on DNA samples from 20 AML patients and 10 AML cell lines. No rearrangements or amplifications of the gene were detected. Taken together, we have mapped C/EBP-epsilon to 14q11.2, a region containing other myeloid and T-lymphoid specific genes. Furthermore, no structural alterations were detected in the C/EBP-epsilon gene.
我们和其他研究人员克隆了一种新的人类基因CCAAT/增强子结合蛋白ε(C/EBP-ε),该基因编码C/EBP基因家族的一个成员。它仅在髓系细胞和T淋巴细胞中表达,并且似乎在诱导几个髓系特异性基因的表达中起重要作用。我们使用基于聚合酶链反应(PCR)的技术检测了93个仓鼠/人类辐射杂种克隆的DNA,以便将C/EBP-ε基因定位于染色体14q11.2(在D14S264和D14S275之间),该区域位于T细胞受体α和δ基因的端粒侧,并且位于包括组织蛋白酶G(CTSG)和糜酶-1(CMA1)在内的其他几个髓系基因产物的着丝粒侧。为了确定C/EBP-ε是否表现为一个改变的肿瘤抑制基因,我们使用在人类C/EBP-ε基因氨基末端0.2 kb范围内鉴定的微卫星序列,对急性髓性白血病(AML)患者和演变为AML的骨髓增生异常综合征(MDS)患者的样本进行杂合性缺失(LOH)研究。在20例演变为AML的MDS病例中有4例(20%)检测到C/EBP-ε基因的等位基因缺失,而在17例AML病例和17例T细胞白血病病例中均未检测到。对37例AML病例和40例MDS病例(包括该基因存在LOH的病例)进行PCR-SSCP基因的突变分析。未发现异常,提示该区域改变的基因不是C/EBP-ε。此外,通过Southern印迹分析检测了20例AML患者和10个AML细胞系的DNA样本中的C/EBP-ε。未检测到该基因的重排或扩增。综上所述,我们已将C/EBP-ε定位于14q11.2,该区域包含其他髓系和T淋巴细胞特异性基因。此外,未在C/EBP-ε基因中检测到结构改变。